Study of adjuvant endocrine treatment for breast cancer reveals cost of noncompliance
Monday, September 21, 2009 - 18:14
in Health & Medicine
Berlin, Germany: The largest study in the world of treatments for post menopausal, hormone positive breast cancer has shown that patients who continue to take exemestane or tamoxifen do significantly better than patients who start to take one or other drug (or tamoxifen followed exemestane) but then stop.